查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085879

關節疼痛注射藥物市場：依分子類型、給藥途徑、適應症、患者年齡層、關節類型和最終用戶分類－2026-2032年全球市場預測

Joint Pain Injections Market by Molecule Type, Route Of Administration, Indication, Patient Age Group, Joint Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，關節疼痛注射市場將成長至 92.8 億美元，複合年成長率為 10.19%。

主要市場統計數據
基準年 2025 47億美元
預計年份：2026年 51.5億美元
預測年份 2032 92.8億美元
複合年成長率 (%) 10.19%

注射型關節痛藥物是治療骨關節炎、發炎性關節炎、運動傷害和退化性肌肉骨骼疾病的重要非手術療法。其需求成長主要受人口老化、肥胖盛行率上升、長期積極生活方式以及在適當情況下延遲或避免關節重建手術的臨床需求所驅動。

此領域涵蓋皮質類固醇、透明質酸、富血小板血漿（PRP）、局部麻醉劑以及新型再生和生物療法。根據世界衛生組織統計，骨關節炎影響全球超過5億人，而美國疾病管制與預防中心的數據顯示，美國有超過5,000萬成年人被醫生診斷出患有骨關節炎。這凸顯了持續需要循證的關節疼痛緩解、關節內注射和門診肌肉骨骼護理。

關節疼痛注射治療領域的變革性變化

關節疼痛注射治療領域正從暫時緩解疼痛轉向以精準引導為基礎、以療效為導向的肌肉骨骼護理。超音波導引注射、門診整形外科中心和綜合疼痛管理路徑正在提高手術精準度、病歷記錄、患者體驗和診所服務能力。

人工智慧（AI）的累積影響

人工智慧 (AI) 正開始影響關節疼痛注射治療的整個流程，從診斷和患者篩選到工作流程自動化和治療效果監測。 AI 驅動的影像工具能夠量化關節腔狹窄、滑液儲存、滑膜炎、軟骨流失和疾病進展，從而為骨關節炎和其他關節疾病的治療決策提供更一致的依據。

主要區域趨勢

在亞太地區，由於人口老化、骨關節炎負擔加重以及整形外科、風濕病科、復健科和疼痛診所的普及，中國、印度、日本、韓國和澳洲的市場正在擴張。日本的超老齡化社會、中國慢性病管理的規模、印度日益成長的私人專科醫療保健以及澳大利亞和韓國完善的影像基礎設施，都促進了影像引導關節注射和循證肌肉骨骼治療的廣泛應用。

對主要經濟和戰略集團的洞察

在東協市場，醫療旅遊、私人醫院的擴張、都市區專科醫療中心的建設以及中產階級日益成長的需求，正在推動整形外科注射和影像引導疼痛管理服務的可及性提升。在海灣合作理事會（GCC）國家，高品質的肌肉骨骼服務、專家主導的診療、醫院現代化以及擴大的門診服務被列為優先事項，這推動了先進注射流程和影像引導下治療技術的應用。

主要國家的概況

在美國，手術量非常高，這得益於門診醫療網路、運動醫學診所、整形外科診所、風濕病科和介入性疼痛管理機構的支持。在加拿大，以指南為基礎的醫療服務取得和公共資助的醫療路徑受到重視；而在墨西哥和巴西，私營部門的擴張、某些都市區的醫療旅遊以及專科醫生的可及性正在推動醫療發展。在英國、德國、法國、義大利和西班牙，公共醫療保險報銷、臨床證據標準、人口老化以及以指南為基礎的關節內注射療法的引入正在重塑醫療保健的提供方式。

為行業領導者提供的實用建議

產業領導者應優先考慮證據的生成，特別是療效比較數據、持續鎮痛、功能改善、重複使用週期中的安全性以及患者報告結局。與整形外科團隊、風濕病網路、門診手術中心、復健機構和影像專家的合作可以改善治療方案的實施、方案的一致性和流程的標準化。

調查方法

本研究整合了來自公共衛生機構、監管機構、臨床指南、同行評審文獻、保險報銷政策和公開資訊的數據。世界衛生組織、美國衛生署、臨床學會指南和監管資料庫等資訊來源被用於檢驗疾病負擔、人口統計因素、治療標準和市場進入條件。

結論

注射療法仍然是治療關節疼痛的重要橋樑，介於保守治療和手術之間，尤其適用於尋求改善關節功能或暫時緩解疼痛的患者。這種需求的出現源自於骨關節炎的流行、人口老化、運動傷害、肥胖相關的關節勞損以及對低成本門診治療的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：關節疼痛注射藥物市場：依分子類型分類

  • 皮質類固醇
    • Betamethasone
    • Methylprednisolone
    • 丙酮化物型曲安奈德
  • 玻尿酸
    • 交聯型
    • 線性
  • 富血小板血漿

第8章：關節疼痛注射藥物市場：依給藥途徑分類

  • 關節內
  • 肌肉內部
    • 深層組織
    • 膚淺
  • 關節週長
    • 地標基地
    • 超音波引導

第9章：關節疼痛注射藥物市場：依適應症分類

  • 骨關節炎
  • 類風濕性關節炎
  • 痛風
  • 黏液囊炎
  • 肌腱炎
  • 滑膜炎

第10章：關節疼痛注射藥物市場：依患者年齡層分類

  • 18歲以下
  • 18-64歲
  • 65歲或以上

第11章：關節疼痛注射藥物市場：以關節類型分類

  • 膝蓋
  • 髖關節
  • 肩膀
  • 踝
  • 彎頭

第12章：關節疼痛注射藥物市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 整形外科診所
  • 風濕病診所

第13章：關節疼痛注射藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：關節疼痛注射劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：關節疼痛注射市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Allergan plc
  • Anika Therapeutics, Inc.
  • Anterogen Co., Ltd.
  • Bioiberica SAU
  • Bioventus LLC
  • Boehringer Ingelheim GmbH
  • Chugai Pharmaceutical Co., Ltd.
  • Contipro as
  • Eli Lilly and Company
  • Ferring BV
  • Fidia Farmaceutici SpA
  • Hangzhou Singclean Medical Products Co., Ltd.
  • LG Chem Ltd.
  • Mylan NV
  • Novartis AG
  • Pacira Pharmaceuticals, Inc
  • Pfizer Inc.
  • Sanofi SA
  • Seikagaku Corporation
  • Shanghai Jingfeng Pharmaceutical Co., Ltd.
  • Smith & Nephew plc
  • Teva Pharmaceutical Industries Ltd.
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-43470FC6083D

The Joint Pain Injections Market is projected to grow by USD 9.28 billion at a CAGR of 10.19% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.70 billion
Estimated Year [2026] USD 5.15 billion
Forecast Year [2032] USD 9.28 billion
CAGR (%) 10.19%

Joint pain injections are a critical non-surgical intervention for osteoarthritis, inflammatory arthritis, sports injuries, and degenerative musculoskeletal disease. Demand is supported by aging populations, higher obesity prevalence, longer active lifestyles, and the clinical need to delay or avoid joint replacement when appropriate.

The landscape spans corticosteroids, hyaluronic acid, platelet-rich plasma, local anesthetics, and emerging regenerative or biologic approaches. WHO reports that osteoarthritis affects more than 500 million people globally, and CDC data show that doctor-diagnosed arthritis affects over 50 million U.S. adults, reinforcing sustained need for evidence-based joint pain relief, intra-articular injections, and outpatient musculoskeletal care.

Transformative Shifts in the Joint Pain Injection Landscape

The joint pain injection landscape is shifting from episodic pain treatment toward precision-guided, outcomes-driven musculoskeletal care. Ultrasound-guided injections, ambulatory orthopedic centers, and integrated pain management pathways are improving procedural accuracy, documentation, patient experience, and clinic throughput.

At the same time, payers and regulators are demanding stronger clinical evidence, especially for higher-cost products and regenerative therapies. Providers are increasingly differentiating through image guidance, standardized injection protocols, real-world outcomes tracking, and patient education around expected duration of relief, safety considerations, and repeat-use limits.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the full joint pain injection pathway, from diagnosis and patient selection to workflow automation and outcomes monitoring. AI-enabled imaging tools can help quantify joint space narrowing, effusion, synovitis, cartilage loss, and structural progression, supporting more consistent treatment decisions in osteoarthritis and other joint disorders.

The cumulative impact is strongest when AI is paired with electronic health records, claims data, imaging archives, and patient-reported outcomes. These systems can help identify likely responders, flag safety risks, optimize scheduling, reduce administrative burden, and generate real-world evidence needed by regulators, payers, and clinical leaders evaluating joint pain injection therapies.

Key Regional Insights

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia face aging populations, rising osteoarthritis burden, and broader access to orthopedic, rheumatology, rehabilitation, and pain clinics. Japan's super-aged population, China's scale of chronic disease management, India's expanding private specialty care, and Australia and South Korea's strong imaging infrastructure support increased use of image-guided joint injections and evidence-based musculoskeletal procedures.

North America remains highly developed due to established ambulatory care networks, advanced imaging adoption, widespread sports medicine services, and high patient awareness of corticosteroid injections, hyaluronic acid injections, and platelet-rich plasma procedures. Latin America is led by Brazil and Mexico, where private healthcare growth, urban specialty clinics, and rising access to orthopedic care support premium injection therapies. Europe is shaped by evidence-based guidelines, health technology assessment, reimbursement discipline, and cost-containment policies, particularly across major public health systems. The Middle East, especially Gulf markets, favors advanced outpatient care, specialist-led musculoskeletal services, and hospital modernization, while Africa remains more access-constrained, with development tied to urban private clinics, essential pain management availability, workforce capacity, and affordability.

Key Economic and Strategic Group Insights

ASEAN markets are gaining momentum as medical tourism, expanding private hospitals, urban specialty centers, and rising middle-class demand improve access to orthopedic injections and image-guided pain procedures. GCC countries prioritize premium musculoskeletal services, specialist-led care, hospital modernization, and outpatient treatment capacity, supporting adoption of advanced injection workflows and imaging-enabled procedures.

The European Union emphasizes regulatory compliance, clinical evidence, pharmacovigilance, medical device oversight, and reimbursement discipline under evolving healthcare frameworks. BRICS countries provide scale through large patient populations, expanding specialty care, chronic disease burden, and local manufacturing potential. G7 markets lead in clinical guidelines, reimbursement governance, digital health infrastructure, real-world evidence generation, and innovation funding, while NATO countries increasingly value resilient medical supply chains, care continuity, and standardized clinical readiness across essential and specialty therapies.

Key Country Insights

The United States is highly procedure-intensive, supported by ambulatory care networks, sports medicine clinics, orthopedic practices, rheumatology services, and interventional pain management providers. Canada emphasizes guideline-based access and publicly funded care pathways, while Mexico and Brazil benefit from private-sector expansion, medical tourism in select urban centers, and growing specialist availability. The United Kingdom, Germany, France, Italy, and Spain are shaped by public reimbursement, clinical evidence thresholds, aging demographics, and guideline-driven adoption of intra-articular injection therapies.

Russia maintains demand through large orthopedic, rheumatology, and rehabilitation needs across a broad population base. China and India offer high-volume growth potential as specialty care expands, chronic musculoskeletal disease awareness rises, and urban hospitals adopt more advanced procedural capabilities. Japan has strong clinical need due to population aging and high osteoarthritis prevalence, while Australia and South Korea combine advanced imaging access, sports medicine expertise, digital health maturity, and high patient awareness to support evidence-based use of joint pain injections.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation, especially comparative effectiveness data, durability of pain relief, functional improvement, safety across repeat-use cycles, and patient-reported outcomes. Partnerships with orthopedic groups, rheumatology networks, ambulatory surgery centers, rehabilitation providers, and imaging specialists can improve adoption, protocol consistency, and procedural standardization.

Organizations should also invest in AI-ready data platforms, physician training, ultrasound-guided injection programs, real-world evidence systems, and payer-facing health economic models. Clear patient segmentation, compliant clinical claims, responsible positioning of regenerative therapies, supply resilience, and region-specific reimbursement strategies will be essential for sustainable growth in joint pain injection therapies.

Research Methodology

The research approach integrates secondary data from public health agencies, regulatory bodies, clinical guidelines, peer-reviewed literature, reimbursement policies, and public disclosures. Sources such as WHO, CDC, OECD, national health ministries, clinical society guidance, and regulator databases are used to validate disease burden, demographic drivers, treatment standards, and market access conditions.

Findings are triangulated through therapy segmentation, regional demand indicators, technology adoption patterns, regulatory pathways, reimbursement dynamics, and stakeholder analysis across manufacturers, providers, payers, distributors, and care-delivery networks. Emphasis is placed on verified evidence, real-world utilization signals, clinical relevance, and defensible interpretation of market drivers without relying on unsupported estimates or forecasts.

Conclusion

Joint pain injections remain an important bridge between conservative therapy and surgery, particularly for patients seeking functional improvement and temporary pain relief. Demand is reinforced by osteoarthritis prevalence, aging populations, sports injuries, obesity-related joint stress, and pressure to manage care in lower-cost outpatient settings.

Future competitiveness will depend on clinical evidence, image-guided precision, payer acceptance, AI-enabled patient stratification, responsible positioning of regenerative therapies, and consistent safety monitoring. Organizations that combine data, training, compliance, access strategy, and real-world outcomes capabilities will be best placed to lead in the evolving joint pain injections landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Joint Pain Injections Market, by Molecule Type

  • 7.1. Corticosteroids
    • 7.1.1. Betamethasone
    • 7.1.2. Methylprednisolone Acetate
    • 7.1.3. Triamcinolone Acetonide
  • 7.2. Hyaluronic Acid
    • 7.2.1. Cross-Linked
    • 7.2.2. Linear
  • 7.3. Platelet-Rich Plasma

8. Joint Pain Injections Market, by Route Of Administration

  • 8.1. Intra-Articular
  • 8.2. Intramuscular
    • 8.2.1. Deep Tissue
    • 8.2.2. Superficial
  • 8.3. Peri-Articular
    • 8.3.1. Landmark-Based
    • 8.3.2. Ultrasound-Guided

9. Joint Pain Injections Market, by Indication

  • 9.1. Osteoarthritis
  • 9.2. Rheumatoid Arthritis
  • 9.3. Gout
  • 9.4. Bursitis
  • 9.5. Tendinitis
  • 9.6. Synovitis

10. Joint Pain Injections Market, by Patient Age Group

  • 10.1. Under 18 Years
  • 10.2. 18 To 64 Years
  • 10.3. 65 Years & Older

11. Joint Pain Injections Market, by Joint Type

  • 11.1. Knee
  • 11.2. Hip
  • 11.3. Shoulder
  • 11.4. Ankle
  • 11.5. Elbow

12. Joint Pain Injections Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Orthopedic Clinics
  • 12.4. Rheumatology Clinics

13. Joint Pain Injections Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Joint Pain Injections Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Joint Pain Injections Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Allergan plc
  • 17.2. Anika Therapeutics, Inc.
  • 17.3. Anterogen Co., Ltd.
  • 17.4. Bioiberica S.A.U.
  • 17.5. Bioventus LLC
  • 17.6. Boehringer Ingelheim GmbH
  • 17.7. Chugai Pharmaceutical Co., Ltd.
  • 17.8. Contipro a.s.
  • 17.9. Eli Lilly and Company
  • 17.10. Ferring B.V.
  • 17.11. Fidia Farmaceutici S.p.A.
  • 17.12. Hangzhou Singclean Medical Products Co., Ltd.
  • 17.13. LG Chem Ltd.
  • 17.14. Mylan N.V.
  • 17.15. Novartis AG
  • 17.16. Pacira Pharmaceuticals, Inc
  • 17.17. Pfizer Inc.
  • 17.18. Sanofi S.A
  • 17.19. Seikagaku Corporation
  • 17.20. Shanghai Jingfeng Pharmaceutical Co., Ltd.
  • 17.21. Smith & Nephew plc
  • 17.22. Teva Pharmaceutical Industries Ltd.
  • 17.23. Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • 17.24. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JOINT PAIN INJECTIONS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL JOINT PAIN INJECTIONS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL JOINT PAIN INJECTIONS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL JOINT PAIN INJECTIONS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL JOINT PAIN INJECTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL JOINT PAIN INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BETAMETHASONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BETAMETHASONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BETAMETHASONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METHYLPREDNISOLONE ACETATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METHYLPREDNISOLONE ACETATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METHYLPREDNISOLONE ACETATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRIAMCINOLONE ACETONIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRIAMCINOLONE ACETONIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRIAMCINOLONE ACETONIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYALURONIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HYALURONIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYALURONIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CROSS-LINKED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CROSS-LINKED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CROSS-LINKED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LINEAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LINEAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LINEAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PLATELET-RICH PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLATELET-RICH PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PLATELET-RICH PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRA-ARTICULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DEEP TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DEEP TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DEEP TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUPERFICIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUPERFICIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUPERFICIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERI-ARTICULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERI-ARTICULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERI-ARTICULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LANDMARK-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LANDMARK-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LANDMARK-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ULTRASOUND-GUIDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ULTRASOUND-GUIDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ULTRASOUND-GUIDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GOUT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GOUT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GOUT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BURSITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BURSITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BURSITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TENDINITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TENDINITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TENDINITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYNOVITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SYNOVITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNOVITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL UNDER 18 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL UNDER 18 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL UNDER 18 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL 18 TO 64 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL 18 TO 64 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL 18 TO 64 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL 65 YEARS & OLDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL 65 YEARS & OLDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL 65 YEARS & OLDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL KNEE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL KNEE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL KNEE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHOULDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SHOULDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHOULDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANKLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANKLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANKLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ELBOW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ELBOW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ELBOW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORTHOPEDIC CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RHEUMATOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RHEUMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RHEUMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 190. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 192. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 193. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. G7 JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 223. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 225. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 226. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 234. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 236. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 237. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL JOINT PAIN INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 312. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 326. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 327. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 328. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. ITALY JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 333. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 334. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 336. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 337. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 338. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 339. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 341. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 344. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 345. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 346. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 347. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 348. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 349. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 350. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY JOINT TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. SPAIN JOINT PAIN INJECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 352. CHINA JOINT PAIN INJECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 355. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY HYALURONIC ACID, 2018-2032 (USD MILLION)
  • TABLE 356. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 357. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 358. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY PERI-ARTICULAR, 2018-2032 (USD MILLION)
  • TABLE 359. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 360. CHINA JOINT PAIN INJECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 361. CHINA